|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7420057||SPROUT PHARMS||Stable polymorph of flibanserin|| |
(1 year, 1 month ago)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9468639||SPROUT PHARMS||Treating sexual desire disorders with flibanserin|| |
(11 months ago)
|US8227471||SPROUT PHARMS||Treating sexual desire disorders with flibanserin|| |
(4 months ago)
|US7151103||SPROUT PHARMS||Method of treating female hypoactive sexual desire disorder with flibanserin|| |
(4 years from now)
Addyi is owned by Sprout Pharms.
Addyi contains Flibanserin.
Addyi has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Addyi are:
Addyi was authorised for market use on 18 August, 2015.
Addyi is available in tablet;oral dosage forms.
Addyi can be used as use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd).
The generics of Addyi are possible to be released after 09 May, 2028.
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic